A5086064363- Helicobacter pylori-related gastroenterology studies
- Veterinary medicine and infectious diseases
- Gastroesophageal reflux and treatments
- Gastric Cancer Management and Outcomes
- Eosinophilic Esophagitis
- Celiac Disease Research and Management
- Clostridium difficile and Clostridium perfringens research
- Gastrointestinal disorders and treatments
- Gastrointestinal motility and disorders
- Microscopic Colitis
- Diverse academic and cultural studies
- Microbial Metabolites in Food Biotechnology
- Infection Control and Ventilation
- Phytochemistry and Bioactive Compounds
- Esophageal and GI Pathology
- Pharmacological Effects of Natural Compounds
- Neuroendocrine Tumor Research Advances
- Cardiovascular Function and Risk Factors
- Skin Protection and Aging
- Vitamin C and Antioxidants Research
- Essential Oils and Antimicrobial Activity
- Intestinal and Peritoneal Adhesions
- Potassium and Related Disorders
- Thyroid Disorders and Treatments
- Respiratory and Cough-Related Research
Università Campus Bio-Medico
2025
University of Bologna
2015-2024
Azienda USL di Bologna
2022-2024
Istituti di Ricovero e Cura a Carattere Scientifico
2023-2024
Istituto delle Scienze Neurologiche di Bologna
2023-2024
Policlinico S.Orsola-Malpighi
2023
Seattle University
2014
Virginia Mason Medical Center
2014
Direction de la Recherche Technologique
2001
Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda
2000
The best approach for Helicobacter pylori management remains unclear. An audit process is essential to ensure clinical practice aligned with standards of care.International multicentre prospective non-interventional registry starting in 2013 aimed evaluate the decisions and outcomes H. by European gastroenterologists. Patients were registered an e-CRF AEG-REDCap. Variables included demographics, previous eradication attempts, prescribed treatment, adverse events outcomes. Data monitoring was...
INTRODUCTION: Antibiotic resistance is one of the main factors that determine efficacy treatments to eradicate Helicobacter pylori infection. Our aim was evaluate effectiveness first-line and rescue against H. in Europe according antibiotics resistance. METHODS: Prospective, multicenter, international registry on management (European Registry Management). All infected culture-diagnosed adult patients registered Spanish Association Gastroenterology-Research Electronic Data Capture from 2013...
Background: Bacterial antibiotic resistance changes over time depending on multiple factors; therefore, it is essential to monitor the susceptibility trends reduce impact effectiveness of various treatments. Objective: To conduct a time-trend analysis Helicobacter pylori antibiotics in Europe. Methods: The international prospective European Registry Management (Hp-EuReg) collected data all infected adult patients diagnosed with culture and antimicrobial testing positive results that were...
ABSTRACT Clarithromycin-based regimens are commonly used as a first-line therapy for Helicobacter pylori -positive patients; however, resistance to clarithromycin has led treatment failures. The aim of this study was evaluate the feasibility using stool samples detect presence H. DNA while concurrently detecting mutations associated with clarithromycin. For purpose, total extracted from 294 raw specimens and -negative patients. TaqMan real-time PCR amplification well predict phenotype...
Adherence to Helicobacter pylori (H. pylori) eradication treatment is a cornerstone for achieving adequate efficacy.
The increasing prevalence of strains resistant to antimicrobial agents is a critical issue in the management Helicobacter pylori (H. pylori) infection.(1) To evaluate primary resistance clarithromycin, metronidazole and levofloxacin (2) assess effectiveness sequential therapy on (3) identify minimum number subjects enrol for evaluating an eradication regimen patients harbouring strains.Consecutive 1682 treatment naïve H. pylori-positive referred upper GI endoscopy between 2010 2015 were...
Helicobacter pylori treatment still remains a challenge for physicians, and no current first-line therapies are able to cure the infection in all treated patients. Two very large meta-analysis studies showed that standard 7—14 days triple fail eradicate H. up 20—25% of patients [Fuccio et al. 2007; Zullo 2007]. In addition, efficacy these regimens is even decreasing worldwide. Indeed, during last few years, different have found success rate following such disappointingly low, with values...
Primary clarithromycin resistance is the main factor affecting efficacy of Helicobacter pylori therapy. This study aimed: (i) to assess concordance between phenotypic (culture) and genotypic (real-time PCR) tests in resistant strains; (ii) search, case disagreement methods, for point mutations other than those reported as most frequent Europe; (iii) compare MICs associated with single mutations. In order perform real-time PCR, we retrieved biopsies from patients whom H. infection was...
Background and aims: the increasing prevalence of strains resistant to antimicrobial agents is a critical issue for management Helicobacter pylori infection. This study aimed evaluate, in Italian naïve patients, H. antibiotic resistance trends their potential predictive factors during last decade. Methods: consecutive positive referred from General Practitioners our Unit January 2009 2019 perform an upper gastrointestinal endoscopy (UGIE), were considered. Each patient underwent 13C-urea...
Italian guideline suggests 10-day sequential or bismuth-based quadruple therapies for first-line Helicobacter pylori treatment. Comparison between these regimens is lacking. We assessed the efficacy of in clinical practice and evaluated role primary bacterial resistance toward clarithromycin metronidazole.Consecutive patients with H. infection were enrolled. Bacterial culture antibiotics susceptibility testing was attempted all cases. Patients received either a therapy esomeprazole 40 mg 10...
Introduction: Eradicating Helicobacter pylori continues to be a challenge, and no treatment regimen is uniformly successful in all treated patients. Triple therapy with rifabutin amoxicillin rescue after consecutive failures. We designed this study test the efficacy of 12-day rifabutin-based triple patients infected multidrug-resistant strains. Methods: Consecutive dyspeptic symptoms at least 1 antibiotic course for H. infection harboring triple-resistant (clarithromycin, metronidazole,...
Treatment of Helicobacter pylori (H. pylori) infection is a challenge for clinicians. The large increase in drug-resistant strains makes the formulation new therapeutic strategies fundamental. frequent onset side effects during antibiotic treatment (mainly due to intestinal dysbiosis) should not be underestimated as it may cause interruption treatment, failure H. eradication and clonal selection resistant bacteria. Probiotic integration can exert dual function: direct antagonistic effect on...
First-line
Rapid diagnostic tools for Helicobacter pylori are important in endoscopy.To assess the accuracy of a new 5 min rapid urease test (UFT300, ABS Srl, Cernusco sul Naviglio, Milan, Italy) and to compare it with 1 h Pyloritek (Serim Laboratories, Elkhart, IN, USA) 24 CLO (Kimberly-Clark Ballard Medical Products, Roswell, GA, USA).Consecutive dyspeptic patients referred our unit endoscopy were prospectively studied. All underwent (13)C-urea-breath test, histology UFT300 (ABS Srl; Italy). In...